专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005046564A3 DIAGNOSIS AND TREATMENT OF LIVER FIBROSIS 审中-公开
标题翻译：肝纤维化的诊断与治疗
公开(公告)号：WO2005046564A3
公开(公告)日：2005-12-15
申请号：PCT/IL2004001048
申请日：2004-11-16
申请人： QUARK BIOTECH INC , SANKYO CO , MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
发明人： MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
IPC分类号： A61K20060101 , A61K31/00 , A61K48/00 , C07H21/04 , C07K16/40 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/00 , A61K2039/505 , C07K16/40 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y301/04004
摘要： The present invention provides methods of treatment of liver fibrosis by identification and isolation of polynucleotide sequences, the expression of which is altered in liver fibrosis. The present invention also relates to the use of these isolated polynucleotides and the polypeptides encoded thereby as probes for diagnosis, for screening of treatment modalities and as targets for modulation in liver fibrosis. In particular, the present invention provides methods, compounds and pharmaceutical compositions for the treatment of liver fibrosis. Novel pharmaceutical compositions comprising oligonucleotides or antibodies are also provided.
摘要翻译：本发明提供了通过鉴定和分离肝纤维化中表达改变的多核苷酸序列来治疗肝纤维化的方法。本发明还涉及这些分离的多核苷酸和由其编码的多肽作为探针用于诊断，筛选治疗模式和作为肝纤维化调节的靶标的用途。特别地，本发明提供了用于治疗肝纤维化的方法，化合物和药物组合物。还提供了包含寡核苷酸或抗体的新型药物组合物。

2. 发明申请

WO2005072057A2 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2005072057A2
公开(公告)日：2005-08-11
申请号：PCT/IL2005/000102
申请日：2005-01-27
申请人： QUARK BIOTECH, INC. , MOR, Orna , FEINSTEIN, Elena
发明人： MOR, Orna , FEINSTEIN, Elena
IPC分类号： A61K48/00 , C07H21/04 , C07K14/705 , C07K16/18 , C07K16/40 , C12N9/10 , C12N15/113 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

3. 发明申请

WO2005041857A2 BONE MORPHOGENETIC PROTEIN (BMP) 2A AND USES THEREOF 审中-公开
标题翻译：骨形态蛋白（BMP）2A及其用途
公开(公告)号：WO2005041857A2
公开(公告)日：2005-05-12
申请号：PCT/IL2004/000924
申请日：2004-10-06
申请人： QUARK BIOTECH, INC. , FUJIWAWA PHARMACEUTICAL CO., LTD. , FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
发明人： FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
IPC分类号： A61K
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenrative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另外的实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经发生性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

4. 发明申请

WO2004111182A3 METHODS FOR CLONING NUCLEIC ACIDS IN A DESIRED ORIENTATION 审中-公开
标题翻译：在想要的方位克隆核酸的方法
公开(公告)号：WO2004111182A3
公开(公告)日：2005-02-24
申请号：PCT/IL2004000515
申请日：2004-06-15
申请人： QUARK BIOTECH INC , EINAT PAZ , ZEVIN-SONKIN DINA , GILAD SHLOMIT
发明人： EINAT PAZ , ZEVIN-SONKIN DINA , GILAD SHLOMIT
IPC分类号： C12N15/10 , C12N15/64 , C12N15/66 , C12P19/34 , C07H21/04
CPC分类号： C12N15/64 , C12N15/10 , C12N15/66
摘要： The present invention provides highly accurate methods for cloning nucleic acids in a desired, pre-defined orientation, and additionally provides for a library of cloned oriented nucleic acids. The ability to control the orientation of a nucleic acid being cloned is highly important in various molecular biology applications.
摘要翻译：本发明提供用于以期望的预定义取向克隆核酸的高度精确的方法，并另外提供克隆的定向核酸文库。控制被克隆的核酸取向的能力在各种分子生物学应用中是非常重要的。

5. 发明申请

WO2004112566A3 DIAGNOSIS AND TREATMENT OF NEPHROPATHY 审中-公开
公开(公告)号：WO2004112566A3
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000566
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61K45/00
摘要： This application is directed to a method for the treatment of nephropathy or kidney fibrosis or glomerulosclerosis or chronic renal insufficiency in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular nephropathy, and to diagnostic aspects related to HNOEL-iso polypeptide.

6. 发明申请

WO2004112565A2 DIAGNOSIS AND TREATMENT OF LIVER, PULMONARY AND CARDIAC FIBROSIS 审中-公开
标题翻译：诊断和治疗肝，肺和心脏纤维化
公开(公告)号：WO2004112565A2
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000565
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： G01N33/576 , A61K2039/505 , C07K14/47 , C07K16/18 , G01N2500/04 , G01N2800/085
摘要： This application is directed to a method for the treatment of fibrosis, preferably liver fibrosis, pulmonary fibrosis and cardiac fibrosis, in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis, and to diagnostic aspects related to HNOEL-iso polypeptide.
摘要翻译：本申请涉及在需要这种治疗的受试者中治疗纤维化，优选肝纤维化，肺纤维化和心脏纤维化的方法，包括向所述受试者施用一定量的足以产生HNO- 显着抑制HNOEL-iso多肽，从而治疗受试者。本申请还涉及获得抑制人HNOEL-iso多肽的化合物的方法。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化以及与HNOEL-iso多肽相关的诊断方面的药物中的用途。

7. 发明申请

WO2004111182A2 METHODS FOR CLONING NUCLEIC ACIDS IN A DESIRED ORIENTATION 审中-公开
标题翻译：在想要的方位克隆核酸的方法
公开(公告)号：WO2004111182A2
公开(公告)日：2004-12-23
申请号：PCT/IL2004/000515
申请日：2004-06-15
申请人： QUARK BIOTECH, INC. , EINAT, Paz , ZEVIN-SONKIN, Dina , GILAD, Shlomit
发明人： EINAT, Paz , ZEVIN-SONKIN, Dina , GILAD, Shlomit
IPC分类号： C12N
CPC分类号： C12N15/64 , C12N15/10 , C12N15/66
摘要： The present invention provides highly accurate methods for cloning nucleic acids in a desired, pre-defined orientation, and additionally provides for a library of cloned oriented nucleic acids. The ability to control the orientation of a nucleic acid being cloned is highly important in various molecular biology applications.
摘要翻译：本发明提供用于以期望的预定义取向克隆核酸的高度精确的方法，并另外提供克隆的定向核酸文库。控制被克隆的核酸取向的能力在各种分子生物学应用中是非常重要的。

8. 发明申请

WO2003063689A2 ISLR GENE AND ITS ASSOCIATION WITH OSTEOARTHRITIS AND OTHER BONE AND CARTILAGE DISORDERS, EXPRESSION PRODUCTS DERIVED THEREFROM, AND USES THEREOF 审中-公开
标题翻译： ISLR基因及其与骨质疏松症和其他骨质疏松症的联系，其衍生的表达产物及其用途
公开(公告)号：WO2003063689A2
公开(公告)日：2003-08-07
申请号：PCT/US2003/002666
申请日：2003-01-29
申请人： QUARK BIOTECH, INC. , SHIONOGI & CO., LTD. , SEGEV, Orit , FEINSTEIN, Elena
发明人： SEGEV, Orit , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： G01N33/5091 , A01K2217/05 , A01K2267/035 , C07K16/22 , C07K2317/76 , C12N2830/008 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/5008 , G01N33/5023 , G01N33/5044 , G01N33/564 , G01N33/6893 , G01N2800/102 , G01N2800/105
摘要： The disclosure relates to the ISLR gene, and functional equivalents thereof, such as those from humans and from mice, probes therefor, tests to identify such genes, expression products of such genes, uses for such genes and expression products, e.g ., in diagnosis (for instance, risk determination), treatment, prevention, or control of osteoarthritis or rheumatoid arthritis or osteoporosis or other bone disorders or conditions or factors or processes which lead to these disorders or conditions ; and to diagnosis, treatment, prevention, or control methods or processes,. as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.
摘要翻译：本公开涉及ISLR基因及其功能等同物，例如来自人和小鼠的那些，其探针，用于鉴定这些基因的测试，这些基因的表达产物，这些基因和表达产物的用途，治疗，预防或控制骨关节炎或类风湿性关节炎或骨质疏松症或其他导致这些疾病或病症的骨病或其他疾病或因素或过程的诊断（例如风险确定）以及诊断，治疗，预防或控制方法或过程。以及其组合物和用于制备和使用这些组合物的方法或方法及其受体和用于获得和使用这些受体的方法或方法。

9. 发明申请

WO2002097057A3 GENE AND POLYPEPTIDE WHICH OPPOSES THE FAS PATHYWAY 审中-公开
公开(公告)号：WO2002097057A3
公开(公告)日：2002-12-05
申请号：PCT/US2002/017390
申请日：2002-05-30
申请人： QUARK BIOTECH, INC. , EINAT, Paz , HAGAR Kalinski
发明人： EINAT, Paz , HAGAR Kalinski
IPC分类号： C07K14/00
摘要： This invention provides a purified polypeptide comprising consecutive amino acids the sequence of which extends from position 242 through position 380 of SEQ ID No:2. This invention also provides a purified polypeptide encoded by a polynucleotide having at least 3o, preferably at least 50, more preferably at least 70, most preferably at least 100 consecutive nucleotides from position 1 to position 108 of SEQ ID No:1. This invention further provides a purified polypeptide encoded by a polynucleotide having at least 30, preferably at least 50, more preferably at least 70, even more preferably at least 100, even more preferably at least 150, most preferably at least 200 consecutive nucleotides from position 340 to position 831 of SEQ ID No:1. This invention further provides an isolated polynucleotide comprising consecutive nucleotides having a sequence as set forth in SEQ ID No:1 and homologs or complements thereof, and this invention further provides an isolated polycleotide comprising consecutive nucleotides having a sequence as set forth from position 93 through position 1232 of SEQ ID No:1 and homologs or complements thereof or comprising consecutive nucleotides having a sequence incorporated in a plasmid designated pMLPD-606 Bac1, deposited under ATCC deposit No.PTA-4348, and homologs or complements thereof.

10. 发明申请

WO02058623A2 INHIBITORS OF SPERMIDINE SYNTHASE FOR THE TREATMENT OF OSTEOARTHRITIS AND CARTILAGE REHABILITATION 审中-公开
标题翻译：用于治疗骨质疏松症和卡他康复的SPIDID合成酶抑制剂
公开(公告)号：WO02058623A2
公开(公告)日：2002-08-01
申请号：PCT/US0148192
申请日：2001-12-12
申请人： QUARK BIOTECH INC , SHIONOGI & CO , BAR DGANIT , FEINSTEIN ELENA , SEGEV ORIT
发明人： BAR DGANIT , FEINSTEIN ELENA , SEGEV ORIT
IPC分类号： G01N33/50 , A61K31/13 , A61K31/155 , A61K31/16 , A61K31/275 , A61K31/52 , A61K31/70 , A61K31/7076 , A61K45/00 , A61P19/02 , A61P43/00 , C12N9/99 , C12Q1/02 , C12Q1/48 , C12Q1/527 , G01N33/15 , A61K
CPC分类号： A61K31/13 , A61K31/155 , A61K31/16 , A61K31/275 , A61K31/52 , A61K31/70 , A61K31/7076 , G01N2333/91171
摘要： This invention provides a method for the treatment of a subject in need of treatment for ostheoarthritis comprising administering to said subject an amount of an inhibitor of spermidien biosynthesis sufficient to effect a substantial inhibition of spermidien biosynthesis. This invention also provides the use of an inhibitor of spermidine biosynthesis in the treatment of a subject in need of treatment of osteoarthritis in an amount sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention further provides a method of preparing a therapeutic composition for the treatment of a subject in need of a treatment for osteoarthritis and the invention further provides a method of identifying an inhibitor of spermidine biosynthesis, whereby the inhibitor is a spermidine synthase inhibitor.
摘要翻译：本发明提供了一种治疗需要治疗骨关节炎的受试者的方法，包括向所述受试者施用一定量的足以实现对实质性生物合成的实质性抑制的精子生物合成抑制剂的量。本发明还提供了亚精胺生物合成抑制剂在治疗需要治疗骨关节炎的受试者中的用量，其用量足以实现对亚精胺生物合成的实质性抑制。本发明还提供了一种制备用于治疗需要治疗骨关节炎的受试者的治疗组合物的方法，本发明还提供了鉴定亚精胺生物合成抑制剂的方法，其中抑制剂是亚精胺合酶抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式